Philip Louis Felgner (born 7 February 1950) is an American biochemists and immunologists, specialized in lipofection technology and genetics.[1] He is one of the developers of the vaccine against the SARS-CoV-2 virus, responsible for COVID-19 pandemic. He is currently the director of the UCI Vaccine Research & Development Center as well as the Protein Microarray Laboratory and Training Facility. [2]
Philip Felgner | |
|---|---|
| Born | Philip Louis Felgner 7 February 1950 Frankenmuth, Michigan, U.S. |
| Alma mater | Michigan State University (B.S., M.S., Ph.D) |
| Known for | Lipofection technologies |
| Awards | Princess of Asturias Awards for Technical and Scientific Research (2021) Robert Koch Prize (2022) |
| Scientific career | |
| Fields | |
| Institutions | University of California, Irvine |
In 1972, he graduated in biochemistry from the Michigan State University, earning his master's degree in 1975 and his Ph.D. in 1978. He did postdoctoral work at the University of Virginia.[3]
In 2021, he was awarded the Princess of Asturias Awards for Technical and Scientific Research along Katalin Karikó, Drew Weissman, Uğur Şahin, Özlem Türeci, Derrick Rossi, and Sarah Gilbert.[4]
In 2022, Philip Felgner was awarded the Robert Koch Prize, one of the stepping-stones to eventual Nobel Prize recognition for scientists in the fields of microbiology and immunology, for his fundamental contributions to the development of lipofection technology, a technology widely used in basic research in medicine for introducing active substances into cells and also the basis of modern mRNA vaccines. [5][6]
In 2022, Philip Felgner was named Fellow by National Academy of Inventors. [7] As of 2022, he has published 280 papers that have been cited 44,000 times and has 53 U.S. patents and 56 foreign patents, including 14 licensed patents. [8]
In 2023, the pioneering work of synthesizing the first cationic lipid (DOTMA) (lipofectin) for DNA and RNA delivery into cells by Philip Felgner was mentioned in the advanced scientific information posted by the Nobel Prize committee for the Nobel Prize in Physiology or Medicine in 2023. [9] [10]
References
edit- ^ Felgner, P L; Gadek, T R; Holm, M; Roman, R; Chan, H W; Wenz, M; Northrop, J P; Ringold, G M; Danielsen, M (November 1987). "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure". Proceedings of the National Academy of Sciences of the United States of America. 84 (21): 7413–7417. Bibcode:1987PNAS...84.7413F. doi:10.1073/pnas.84.21.7413. ISSN 0027-8424. PMC 299306. PMID 2823261.
- ^ "Phil Felgner, PhD, joins Physiology & Biophysics | Department of Physiology and Biophysics | School of Medicine | University of California, Irvine". www.physiology.uci.edu. Retrieved 2024-10-16.
- ^ Philip L. Felgner UCI profile
- ^ "Katalin Karikó, Drew Weissman, Philip Felgner, Uğur Şahin, Özlem Türeci, Derrick Rossi, and Sarah Gilbert, Princess of Asturias Award for Technical and Scientific Research 2021". Princess of Asturias Foundation. 23 June 2021.
- ^ "UCI professor wins prestigious Robert Koch prize | UCI Health | Orange County, CA". www.ucihealth.org. Retrieved 2024-10-16.
- ^ "Robert Koch Award". www.robert-koch-stiftung.de. Retrieved 2024-10-16.
- ^ "Fellows". NAI. Retrieved 2024-10-16.
- ^ taylorrr (2022-12-13). "Phil Felgner named Fellow by National Academy of Inventors". Institute for Immunology. Retrieved 2024-10-16.
- ^ "The Nobel Prize in Physiology or Medicine 2023". NobelPrize.org. Retrieved 2024-10-16.
- ^ "Nobel Prize in physiology or medicine cites UCI's Philip Felgner – UC Irvine News". news.uci.edu. Retrieved 2024-10-16.
 | This biographical article related to medicine is a stub. You can help Wikipedia by expanding it. |